PCM
NBIX icon

Penserra Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Penserra Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,088
Closed -$143K – 1362
2023
Q4 		$143K Sell
1,088
-5,280
-83% -$608K ﹤0.01% 836
2023
Q3 		$716K Buy
+6,368
New +$671K 0.01% 424
2020
Q3 		– Sell
-8,162
Closed -$995K – 1000
2020
Q2 		$995K Buy
+8,162
New +$902K 0.05% 271
2019
Q1 		– Sell
-1,216
Closed -$86K – 775
2018
Q4 		$86K Buy
+1,216
New +$117K 0.01% 389

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Penserra Capital Management's NBIX Position: Q1 2024 in Review

Penserra Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 1,088 shares — an estimated $143K sold.

Penserra Capital Management first reported a position in NBIX in Q4 2018 and held it in 4 quarters. The position peaked at $995K in Q2 2020. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Penserra Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Penserra Capital Management sold 1,088 Neurocrine Biosciences shares in Q1 2024, an estimated $143K.
  • Penserra Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 4 quarters.
  • Penserra Capital Management's Neurocrine Biosciences position peaked at $995K in Q2 2020.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Penserra Capital Management's 13F filing for Q1 2024, filed 15 May 2024.